Mirabella Financial Services LLP Sells 38,971 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Mirabella Financial Services LLP trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 61.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,844 shares of the medical research company’s stock after selling 38,971 shares during the period. Mirabella Financial Services LLP’s holdings in IQVIA were worth $5,887,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. Advisors Asset Management Inc. grew its holdings in shares of IQVIA by 106.4% in the 1st quarter. Advisors Asset Management Inc. now owns 1,298 shares of the medical research company’s stock valued at $328,000 after buying an additional 669 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of IQVIA by 7.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 886,948 shares of the medical research company’s stock worth $224,301,000 after acquiring an additional 60,079 shares in the last quarter. Caxton Associates LP acquired a new stake in shares of IQVIA during the first quarter worth about $842,000. B. Riley Wealth Advisors Inc. lifted its holdings in shares of IQVIA by 13.9% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $902,000 after purchasing an additional 436 shares in the last quarter. Finally, Meiji Yasuda Life Insurance Co grew its position in shares of IQVIA by 24.0% in the 1st quarter. Meiji Yasuda Life Insurance Co now owns 1,810 shares of the medical research company’s stock valued at $458,000 after purchasing an additional 350 shares during the period. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on IQV. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. BTIG Research reduced their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Performance

NYSE IQV opened at $204.45 on Monday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm’s fifty day moving average price is $222.67 and its two-hundred day moving average price is $227.16. The firm has a market capitalization of $37.11 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.